ALK lancerer ny vækststrategi og finansielle ambitioner for 2028
03. Juni 2024 12:02 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag meddelt, at bestyrelsen har vedtaget en ny selskabsstrategi (Allergy+) og finansielle ambitioner for 2028. Målet med Allergy+ er at udbygge ALK’s...
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
03. Juni 2024 01:00 ET
|
ALK Abello
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK...
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
30. Mai 2024 07:44 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for...
Listen in on ALK’s Capital Markets Day on 4 June 2024
29. Mai 2024 04:56 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00. We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital...
Three-month interim report (Q1) 2024 (unaudited) - English version only
02. Mai 2024 13:43 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth...
Three-month interim report (Q1) 2024 (unaudited)
02. Mai 2024 13:43 ET
|
ALK Abello
Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European...
ALK opjusterer sine forventninger til salget for helåret
02. Mai 2024 13:26 ET
|
ALK Abello
ALK opjusterer sine salgsforventninger for helåret ALK (ALKB:DC / OMX: ALK B / AKBLF) annoncerede i dag, at salgsforventningerne for helåret 2024 er blevet opjusteret. Omsætningen forventes nu at...
ALK upgrades its full-year revenue outlook
02. Mai 2024 13:26 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The...
Invitation til præsentation af ALK’s regnskab for første kvartal fredag den 3. maj 2024
24. April 2024 10:35 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første tre måneder af 2024 (Q1) om morgenen fredag den 3. maj 2024. ALK afholder senere samme dag kl. 12.30 (CET) en...
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
24. April 2024 10:35 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET,...